Study of QL2107 plus chemo vs. Keytruda for advanced lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-squamous non-small cell lung cancer that has spread to other parts of the body.
- Your lung cancer does not have EGFR mutations or ALK gene changes.
- You are between 18 and 75 years old.
- You are in generally good health (ECOG score 0 or 1, meaning you are fully active or only limited in strenuous activity).
- You have not had radiation to the chest area within the last 6 months, or any radiation within the last 7 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (QL1706 and bevacizumab) with or without chemotherapy for people with advanced non-squamous lung cancer whose cancer worsened after prior immunotherapy. It may offer a new option for those with low PD-L1 levels.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial compares a new medicine called QL2107 to the approved drug Keytruda in people with non-small cell lung cancer (NSCLC) that has been removed completely by surgery and treated with chemotherapy. The goal is to see if QL2107 works similarly to Keytruda in preventing the cancer from coming back.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
This trial tests a new combination of drugs (QL1706 plus chemo and bevacizumab) for people with advanced lung cancer that has a specific gene mutation, has stopped responding to targeted therapy, and has high PD-L1 levels. It aims to see if this approach can help when other treatments have stopped working.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.